spacer
home > ebr > spring 2019 > the road to success
PUBLICATIONS
European Biopharmaceutical Review

The Road to Success

When thinking of biomarkers and their role in delivering personalised medicine, most will picture recent advances in oncology and, in particular, those that have arisen following seminal developments in human genomics, including the publishing of the human genome sequence in 1999. However, in reality, biomarkers have been around for much longer and have been driving a move to a more personalised approach to medicine for many years. This article examines both historical and modern groundbreaking examples to explain and exemplify the different types of biomarkers and their use in medicine.

Defining Biomarkers

There are many definitions of biomarkers, but this article will focus on one from a WHO collaborative study which defined a biomarker as “any substance, structure, or process that can be measured in the body or its products and influence or predict the incidence of outcome or disease” (1). If this definition is extended to include the effects of treatments, interventions, and exposure to environmental agents such as chemicals or nutrients, the possibilities are endless.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Karen Hills is Director of Marketing and Medical Affairs at PredictImmune, focussing on the launch of new products and clinical studies. Her background includes medical and marketing roles in both startup companies and Big Pharma. Karen has a PhD from the University of Cambridge and an Executive MBA from London Business School, UK.

Professor Ken Smith is Professor of Medicine and Head of the Department of Medicine at the University of Cambridge and is Chief Medical Officer at PredictImmune. He trained in nephrology and clinical immunology and completed a PhD at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia. His lab runs a translational programme in autoimmune disease (particularly IBD, vasculitis, and SLE) that has led to the discovery of a novel prognosis-predicting biomarker currently in clinical trials and the identification of genes and pathways involved in disease pathogenesis.
spacer
Dr Karen Hills
spacer
spacer
spacer
Professor Ken Smith
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder


More info >>

White Papers

EU GDP Guidelines: Implications for Shipping Clinical Materials into the European Market

PCI Pharma Services

Recently, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mold on paracetamol (acetaminophen) tablets (1). It discovered the product was shipped by sea from India to multiple companies in the UK at temperatures reaching up to 60 degrees Celsius. Labeling for paracetamol tablets typically states they should be kept below 30 degrees Celsius. In addition, MHRA discovered the humidity levels exceeded 80 percent during shipping, which is too high for the packaging that was used.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement